Division of Cardiology, Abington Jefferson Health, Abington, Pennsylvania.
Division of Cardiology, Cleveland Clinic, Internal Medicine, Cleveland, Ohio.
J Cardiovasc Med (Hagerstown). 2021 Jul 1;22(7):586-593. doi: 10.2459/JCM.0000000000001172.
We sought to determine the racial and ethnical disparities in the delivery of TAVR and to evaluate the in-hospital outcomes and utilization of TAVR stratified by patient ethnicity.
Using a national inpatient sample database between 2011 and 2015, we identified all adult patients who had TAVR. Races were identified and white race was set as control. Multiple logistic regression analysis was performed for the primary outcome of in-hospital mortality.
Out of 58 174 patients who underwent TAVR, 50 809 (87.3%) were white, 2327 (4.0%) were black, 2311 (4.0%) were Hispanic, 640 (1.1%) Asian, 105 (0.2%) Native American and 1982 (3.4%) of other ethnicities. We found a statistically significant linear uptrend in the utilization of TAVR in patients of all races between the years 2011 and 2015. White, black, Hispanic and Native American patients had a downward linear trend for mortality during the studied years (P ≤ 0.005 for all). Black patients had lower in-hospital mortality [2.8 vs. 3.6%, odds ratio (OR) = 0.62; 95% confidence interval (CI) 0.44, 0.81 P < 0.001] compared with white patients, whereas Hispanic patients and Native Americans had higher in-hospital mortality compared with white patients (4.5% OR 1.26; 95% CI 1.01, 1.56 P = 0.041), (9.5% OR 4.44; 95% CI 2.25, 8.77 P < 0.001), respectively.
Overall, TAVR utilization is associated with lower mortality. There is a rising trend in utilization of TAVR in the black population with a significantly favorable mortality trend compared with the white population.
我们旨在确定 TAVR 治疗中的种族和民族差异,并评估按患者种族分层的 TAVR 的住院结局和使用情况。
使用 2011 年至 2015 年期间的全国住院患者样本数据库,我们确定了所有接受 TAVR 的成年患者。鉴定了种族,将白种人设定为对照组。对住院死亡率这一主要结局进行了多项逻辑回归分析。
在 58174 例接受 TAVR 的患者中,50809 例(87.3%)为白种人,2327 例(4.0%)为黑种人,2311 例(4.0%)为西班牙裔,640 例(1.1%)为亚洲人,105 例(0.2%)为美洲原住民,1982 例(3.4%)为其他种族。我们发现,2011 年至 2015 年间,所有种族的 TAVR 使用量呈统计学上显著的线性上升趋势。白种人、黑种人、西班牙裔和美洲原住民患者的死亡率在研究期间呈线性下降趋势(所有 P≤0.005)。黑种人患者的住院死亡率较低[2.8%比 3.6%,比值比(OR)=0.62;95%置信区间(CI)0.44,0.81,P<0.001],而西班牙裔和美洲原住民患者的住院死亡率高于白种人患者(4.5% OR 1.26;95% CI 1.01,1.56,P=0.041),(9.5% OR 4.44;95% CI 2.25,8.77,P<0.001)。
总体而言,TAVR 的使用与死亡率降低相关。TAVR 的使用在黑人群体中呈上升趋势,与白人群体相比,死亡率呈显著有利趋势。